Transcription of Public Assessment Report Decentralised Procedure ...
{{id}} {{{paragraph}}}
Example: air traffic controller
Public Assessment Report Decentralised Procedure ...
PAR sayanaject 104 mg suspension for injection UK/H/5497/001/DC 1 Public Assessment Report Decentralised Procedure sayanaject 104 mg suspension for injection ( medroxyprogesterone acetate) Procedure No: UK/H/5497/001/DC UK Licence No: PL 00057/1498 Pfizer Limited PAR sayanaject 104 mg suspension for injection UK/H/5497/001/DC 2 LAY SUMMARY sayanaject 104 mg suspension for injection ( medroxyprogesterone acetate, suspension for injection, 104 mg) This is a summary of the Public Assessment Report (PAR) for sayanaject 104 mg suspension for injection (PL 00057/1498; UK/H/5497/001/DC). It explains how sayanaject 104 mg suspension for injection was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use sayanaject 104 mg suspension for injection. For practical information about using sayanaject 104 mg suspension for injection, patients should read the package leaflet or contact their doctor or pharmacist.
PAR Sayanaject 104 mg suspension for injection UK/H/5497/001/DC 2 LAY SUMMARY Sayanaject 104 mg suspension for injection (medroxyprogesterone acetate, suspension for injection, 104 mg)
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
PROVERA Medroxyprogesterone acetate, PROVERA ® Medroxyprogesterone acetate, Medroxyprogesterone acetate, USPI medroxyprogesterone acetate - Depo, Medroxyprogesterone, Product List – 2010, Suspension for injection medroxyprogesterone acetate Single-dose, Approved Prescription Products for Menopausal, Public Assessment Report Mutual Recognition, Public Assessment Report Mutual Recognition Procedure, Pfizer